



Article Low Energy Status under Methionine Restriction Is Essentially Independent of Proliferation or Cell Contact Inhibition

Corinna Koderer ^{1,†}, Werner Schmitz ^{2,†}, Anna Chiara Wünsch ¹, Julia Balint ¹, Mohamed El-Mesery ³, Julian Manuel Volland ¹, Stefan Hartmann ¹, Christian Linz ¹, Alexander Christian Kübler ¹ and Axel Seher ^{1,*}

- ¹ Department of Oral and Maxillofacial Plastic Surgery, University Hospital Wuerzburg, D-97070 Wuerzburg, Germany; corinna.koderer@posteo.de (C.K.); wuenschanna@outlook.de (A.C.W.); julia-balint@web.de (J.B.); julian_volland@gmx.de (J.M.V.); hartmann_s2@ukw.de (S.H.); linz_c@ukw.de (C.L.); kuebler_a@ukw.de (A.C.K.)
- ² Department of Biochemistry and Molecular Biology, Biocenter, D-97074 Wuerzburg, Germany; wschmitz@biozentrum.uni-wuerzburg.de
- ³ Department of Biochemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt; m_elmesery@mans.edu.eg
- * Correspondence: seher_a@ukw.de; Tel.: +49-931-201-74841
- + These authors contributed equally to this work.

Abstract: Nonlimited proliferation is one of the most striking features of neoplastic cells. The basis of cell division is the sufficient presence of mass (amino acids) and energy (ATP and NADH). A sophisticated intracellular network permanently measures the mass and energy levels. Thus, in vivo restrictions in the form of amino acid, protein, or caloric restrictions strongly affect absolute lifespan and age-associated diseases such as cancer. The induction of permanent low energy metabolism (LEM) is essential in this process. The murine cell line L929 responds to methionine restriction (MetR) for a short time period with LEM at the metabolic level defined by a characteristic fingerprint consisting of the molecules acetoacetate, creatine, spermidine, GSSG, UDP-glucose, pantothenate, and ATP. Here, we used mass spectrometry (LC/MS) to investigate the influence of proliferation and contact inhibition on the energy status of cells. Interestingly, the energy status was essentially independent of proliferation or contact inhibition. LC/MS analyses showed that in full medium, the cells maintain active and energetic metabolism for optional proliferation. In contrast, MetR induced LEM independently of proliferation or contact inhibition. These results are important for cell behaviour under MetR and for the optional application of restrictions in cancer therapy.

Keywords: methionine restriction; caloric restriction; mass spectrometry; LC/MS; liquid chromatog-raphy/mass spectrometry; metabolomics; L929; amino acid; proliferation; contact inhibition

1. Introduction

A late event in the development of cancer is unlimited proliferation and the resulting space-occupying lesion. Although the pathological causes of carcinogenesis are diverse [1] and proliferation is an important biological process regulated and influenced by numerous factors [2–4], this process can be reduced to two simple regulating components: the availability of energy and mass. Both factors are essential, and proliferation can be fundamentally regulated via both elements. In the case of mass, amino acids are paramount. These molecules form the main mass of the cell [5] as structural proteins, enzymes, and numerous metabolites. In the case of energy, carbohydrates and lipids are more important initially and essentially result in the energy currencies ATP and NAD(P)H.

Continuous limitation of the mass via protein (PR) or amino acid restriction (AR) or in the case of energy by caloric restriction (CR) has a strong positive effect on almost all organisms. The absolute/relative lifespan is significantly extended, and the risk of age-associated cardiovascular disease, type II diabetes, and cancer is substantially reduced [6–8]. Therefore, common to all these forms of restriction is the induction of "low energy metabolism"



Citation: Koderer, C.; Schmitz, W.; Wünsch, A.C.; Balint, J.; El-Mesery, M.; Volland, J.M.; Hartmann, S.; Linz, C.; Kübler, A.C.; Seher, A. Low Energy Status under Methionine Restriction Is Essentially Independent of Proliferation or Cell Contact Inhibition. *Cells* **2022**, *11*, 551. https://doi.org/10.3390/ cells11030551

Academic Editor: Mariano Bizzarri

Received: 12 January 2022 Accepted: 3 February 2022 Published: 4 February 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). (LEM), which manifests itself at the cellular level mainly in two biological responses: inhibition of proliferation and induction of autophagy. Both processes are important for resource conservation and recycling [9]. The implementation of the various forms of restriction has already been well elucidated at the molecular level. In general terms, a cell is either growing/dividing or not. Many sensors enable the cell to continuously measure the levels of energy and necessary building blocks and to determine whether cell division is possible and energetically sensible. With the help of a sophisticated molecular network, both intracellular and extracellular signals can be permanently recorded and processed. The AMP/ATP ratio, for example, is measured by AMP kinase (AMPK) [10]; the NAD⁺ level via sirtuins [11]; and the content of selected amino acids (e.g., leucine, arginine, glutamine, serine, and methionine) via various protein complexes, such as SAMTOR, which can be used to indirectly measure the methionine content via the intermediate S-adenosylmethionine (SAM) [12]. A deficiency of one of the necessary resources leads to the activation of different proteins and protein complexes, which in turn can have an inhibitory effect on one of the central switching sites, mechanistic target of rapamycin (mTOR). The sum of signals converging on mTOR determines whether mTOR actively promotes proliferation/growth or whether the cell switches to LEM by inhibiting mTOR and activating autophagy, among other things [13–15]. Extracellular signals from growth factors, such as the growth hormone (GH)-insulin-like-growth factor (IGF1) axis, also play a role here. IGF1 induced by GH and mostly secreted by the liver, mTOR, for example, is activated intracellularly via the PI3K/Akt pathway via the IGF1 receptor [16].

One of the simplest and most effective forms of restriction is methionine restriction (MetR), which is very easy to implement in cell culture by simply removing the amino acid in the medium. Many of the mechanisms induced by MetR are consistent with AR, PR, and CR [17–19]. In a previous work, we demonstrated that the murine cell line L929 reacts rapidly and efficiently to MetR. Proliferation was inhibited after 24 h, and the analysis over a period of 5 days of more than 150 different metabolites belonging to different classes [amino acids, urea and tricarboxylic acid cycle (TCA) cycles, carbohydrates, etc.] by liquid chromatography/mass spectrometry (LC/MS) defines a metabolic fingerprint and enables the identification of specific metabolites representing normal or MetR conditions. In addition to the large fingerprint with numerous metabolites, the induction of LEM can potentially be analysed using a small footprint with selected metabolites that are specific/characteristic of MetR-induced LEM and are composed of the combination of acetoacetate, creatine, spermidine, GSSG, UDP-glucose, pantothenate, and ATP [20].

Cells in culture usually have a similar metabolism to cancer cells. The reason lies in the proliferation itself, which leads to a change in metabolism called the Warburg effect. Thus, the Warburg effect is not a specific characteristic of cancer cells but of proliferating cells [4]. However, in contrast to tumour cells, many cells in culture retain the native capacity for contact inhibition, i.e., that adjacencies, including those caused by cell-cell contacts, lead to inhibition of proliferation [21–23].

In this work, we investigated the extent to which contact inhibition affects the metabolism of L929 cells and whether inhibition of proliferation induces a metabolic profile equivalent to that of LEM. For comparison, we cultured L929 cells under the same conditions under MetR. Over a period of 5 days, LC/MS was used to profile more than 150 metabolites every 24 h. In addition, the profiles were compared with the metabolic profiles of cells under proliferative conditions from the previous work mentioned above.

Interestingly, the cells retain their characteristic profile largely independent of proliferation. In principle, proliferation and contact inhibition have a slight influence on the metabolic profile, but the determining factor is whether it is full medium or MetR. Under full medium, cells show a tendency to maintain active and energetic metabolism to be prepared for optional proliferation at any time. In contrast, MetR induces a metabolism equivalent to that of LEM under both proliferative and confluent conditions. These results are important, as they demonstrate the possibility of inducing cells to develop LEM in principle. This phenomenon can be important in cancer therapy, among other applications.

2. Materials and Methods

2.1. Cell Culture

The murine fibroblast cell line L929 was purchased from the Leibniz Institute, DSMZ-German Collection of Microorganisms and Cell Cultures GmbH (Braunschweig, Germany). The parent L strain was derived from normal subcutaneous areolar and adipose tissue of a 100-day-old male C3H/An mouse. NCTC clone 929 (Connective tissue, mouse) of strain L was derived in March, 1948. Strain L was one of the first cell strains to be established in continuous culture, and clone 929 was the first cloned strain developed. Clone 929 was established (by the capillary technique for single cell isolation) from the 95th subculture generation of the parent strain (information from the homepage of ATCC—American Type Culture Collection: https://www.atcc.org/products/ccl-1 (accessed on 2 January 2022)). The cells were cultured in RPMI 1640 medium (Gibco, Life Technologies; Darmstadt, Germany) with 10% FCS (Sigma-Aldrich, Darmstadt, Germany) and 1% penicillin/streptomycin (P/S; 100 U/mL penicillin and 100 μ g/mL streptomycin, Thermo Fisher Scientific, Darmstadt, Germany) at 37 °C in a humidified atmosphere containing 5% CO₂. The basis medium lacked methionine. For full medium, 15 mg/L methionine (Sigma-Aldrich, Darmstadt, Germany) was added.

2.2. ImageXpress Pico Automated Cell Imaging System—Digital Microscopy (Pico Assay)

Cells were seeded at 10,000 cells in 100 μ L of culture medium per well of a 96-well plate and incubated overnight. The following day, the cells were incubated in complete or methionine-free media. The incubation time is stated in the corresponding figure legend. For staining, 10 μ L of Hoechst staining solution [1:200 dilution in medium of Hoechst 33342 (Thermo Fisher, Darmstadt, Germany) (10 mg/mL in H₂O)] was added to each well, and the samples were analysed after a 20–30 min incubation. Wells were analysed with an ImageXpress Pico Automated Cell Imaging System (Molecular Devices, San Jose, CA, USA) via automated digital microscopy. The cells were analysed with transmitted light and in the DAPI channel at 4× magnification. The complete area of every well was screened. Focus and exposure time were set via autosetup and controlled by analysing three to four test wells. Finally, every result was confirmed visually, and 95% or more of cells were counted and analysed.

2.3. L929 Experiments for LC/MS

L929 cells were seeded in 20 mL of medium in 15 cm Petri dishes, and every value was measured in triplicate. For cell confluence, 3×10^6 cells were seeded, and after 48 h, cells were stimulated with complete or Met(–) media. In an earlier work, 1×10^{6} cells/Petri dish were seeded under proliferative conditions for days 1, 2, and 3, and 5×10^5 cells were seeded for days 4 and 5 to prevent confluence during the test period [20]. The media used for stimulation were prepared from methionine-free RPMI medium. The complete medium (control) contained 15 mg/L methionine, and the Met(-) medium lacked methionine (amino acid from Sigma-Aldrich, Darmstadt, Germany). All media contained 10% FCS (Sigma-Aldrich, Darmstadt, Germany) and 1% P/S (100 U/mL penicillin and 100 µg/mL streptomycin (Thermo Fisher Scientific, Darmstadt, Germany)). After seeding, the cells were incubated with 20 mL of complete medium or 20 mL of methionine-free medium per dish. Before harvesting, 1 mL of the supernatant was stored for analysis. The remaining medium was then removed, and the cells were washed with 10 mL of PBS and detached with 3 mL of trypsin/EDTA (Thermo Fisher Scientific, Darmstadt, Germany). After the addition of 7 mL of the appropriate medium, the absolute cell number in the suspensions was analysed with the automated cell counter EVETM (NanoEntek (VWR, Darmstadt, Germany)). Each sample was measured four times, and the mean value was calculated to obtain an accurate result. Pellets with 1×10^6 cells were produced by centrifugation (5 min at 1200 rpm at RT). Until the LC/MS analysis, all samples were stored at -20 °C.

2.4. LC/MS

Analysis of water-soluble metabolites in cell extracts and culture media.

Cells: After the addition of 0.5 mL of MeOH/CH₃CN/H₂O (50/30/20, v/v/v) containing 10 µM lamivudine, cell pellets were homogenized by ultrasound treatment (10 × 1 s, 250 W output energy). Media: One hundred microliters of culture medium was combined with 0.4 mL of MeOH/CH₃CN (50/30, v/v) containing 10 µM lamivudine. The external standard lamivudine was not used for absolute metabolite quantification but was used as a quality control to compensate for eventually occurring technical issues. As quality control and for the determination of the corresponding retention times, most of the annotated metabolites (which are commercially available) were run as mixtures of pure compounds under identical experimental conditions. General procedure: The resulting suspension was centrifuged (20 kRCF for 2 min in an Eppendorf centrifuge 5424), and the supernatant was applied to a C18-SPE column that was activated with 0.5 mL of CH₃CN and equilibrated with 0.5 mL of MeOH/CH₃CN/H₂O (50/30/20, v/v/v). The SPE eluate was evaporated in a vacuum concentrator. The resulting pellet was dissolved in 50 µL (cell extracts) or 500 µL (media extracts) of 5 mM NH₄OAc in CH₃CN/H₂O (25%/75%, v/v).

LC parameters: Mobile phase A consisted of $5 \text{ mM NH}_4\text{OAc}$ in CH₃CN/H₂O (5/95, v/v), and mobile phase B consisted of $5 \text{ mM NH}_4\text{OAc}$ in CH₃CN/H₂O (95/5, v/v).

After the application of 3 μ L of the sample to a ZIC-HILIC column (at 30 °C), the LC gradient program was as follows: 100% solvent B for 2 min, a linear decrease to 40% solvent B over 16 min, maintenance at 40% solvent B for 9 min, and an increase to 100% solvent B over 1 min. The column was maintained at 100% solvent B for 5 min for column equilibration before each injection. The flow rate was maintained at 200 μ L/min. The eluent was directed to the ESI source of the QE-MS from 1.85 min to 20.0 min after sample injection.

The MS parameters were as follows: scan type, full MS in the positive-and-negative mode (alternating); scan range, 69–1000 m/z; resolution, 70,000; AGC-target, 3E6; maximum injection time, 200 ms; sheath gas, 30; auxiliary gas, 10; sweep gas, 3; spray voltage, 3.6 kV (positive mode) or 2.5 kV (negative mode); capillary temperature, 320 °C; S-lens RF level, 55.0; and auxiliary gas heater temperature, 120 °C. Annotation and data evaluation: Peaks corresponding to the calculated monoisotopic masses (MIM +/- H⁺ ± 2 mMU) were integrated using TraceFinder software (Thermo Scientific, Bremen, Germany). Materials: Ultrapure water was obtained from a Millipore water purification system (Milli-Q Merck Millipore, Darmstadt, Germany). HPLC–MS solvents, LC–MS NH₄OAc, and lamivudine were purchased from Merck (Darmstadt, Germany). The RP18-SPE columns were 50 mg of Strata C18-E (55 µm) in 1-mL tubes (Phenomenex, Aschaffenburg, Germany). The sonifier was a Branson Ultrasonics 250 equipped with a 13-mm sonotrode (Thermo Scientific, Bremen, Germany).

LC/MS system: A Thermo Scientific Dionex UltiMate 3000 UHPLC system linked to a Q Exactive mass spectrometer (QE-MS) equipped with a HESI probe (Thermo Scientific, Bremen, Germany) was used. The samples were analysed with a high-resolution mass spectrometer, allowing the generation of XIC data that were analysed by applying a very narrow m/z margin (+/- 3 mMU). The particle filter was a Javelin filter with an ID of 2.1 mm (Thermo Scientific, Bremen, Germany). The UPLC-precolumn was a SeQuant ZIC-HILIC column (5-µm particles, $20 \times 2 \text{ mm}$) (Merck, Darmstadt, Germany). The UPLC column was a SeQuant ZIC-HILIC column (3.5-µm particles, $100 \times 2.1 \text{ mm}$) (Merck, Darmstadt, Germany).

Raw Data Analysis and Value Generation (in short):

LC/MS analyses were carried out in four independent experiments at 24, 48, 72, 96 and 120 h, with each value obtained from triplicate measurements. Metabolites were quantified in cell pellets and corresponding supernatants (media) under methionine-supplemented and methionine-free conditions (12 samples per time point in total). The resulting peak areas were normalized against that of lamivudine as an external standard. From this, the mean value and standard deviation were calculated for each triplicate. For better comparisons, the

values were converted to percentages. For the values of the media, the control measurement of the medium used was defined as 100%. For the cell pellets, the highest measured value in each test series within an experiment was defined as 100%. From these values, the average mean values from the four experiments were then summarized in the individual tables. For a better overview, the results were rounded to natural numbers and shown as a heatmap. The corresponding colour range is indicated individually under each table. The raw data and results for the two profiles are added as excel files in the Supplementary Material as Table S1 (proliferative profile) and Table S2 (non-proliferative profile).

2.5. Statistical Analysis

Data collection and plotting were performed with Excel (Microsoft, Redmond, WA, USA) and GraphPad Prism (version 6.04; GraphPad Software, San Diego, CA, USA) software. Statistical analysis was performed using GraphPad. Comparisons between different groups were performed by applying one-way ANOVA followed by the Tukey–Kramer multiple comparison test (*** p < 0.001).

3. Results

In a previous work, we established the murine cell line L929 as a model system to analyse MetR [20]. Thus, we deliberately chose a murine cell line for several reasons. First, much of the research on different restriction forms has been studied in rodent models. The mouse has established itself as a successful model system to analyse energy metabolism in this context [24]. The use of a murine system thus allows a better comparison with results from the literature. Second, the murine metabolism is considerably faster and more efficient. If one compares the metabolic equivalents energy/body weight/time (Kcal/g/h), the mouse has a metabolic turnover up to $100 \times$ higher than humans [25–27]. For this reason, murine cells are much better suited for analyses of the metabolome than human cells. A third reason is that a large number of mechanisms are strongly conserved or are implemented in a very similar way. With the beginning of the first cell, there was a great selection in the areas of energy and mass, which led to a large number of basic mechanisms. This is why, as already mentioned, the restrictions work in the most organisms, from yeast to nematodes, from Drosophila and rodents to primates and even humans [6,8]. Many conserved mechanisms are used, which, although adapted in the individual species, are nevertheless highly conserved. mTOR and the sirtuins are just two examples [11,14]. The murine cell line L929 has fulfilled these conditions. In addition, this cell line corresponds to fibroblasts, which are characterised by a general profile in contrast to neurons or hepatocytes, which are highly specialised.

As previously reported, proliferation was almost completely inhibited in L929 after 24 h. Importantly, over the study period of 120 h, even complete MetR (0 mg/mL) did not lead to a significant decrease in cell number, e.g., due to cell death (Figure 1a). In addition, the cells became increasingly sensitive to a decreasing methionine level over time (Figure 1b).

To determine how contact inhibition under full medium and under MetR affects metabolism, we seeded an appropriate number of cells on cell culture dishes and incubated them for 48 h before stimulation until the cells formed a confluent cell layer. Then, the cells were incubated with full medium or Met(-) medium (0 mg/mL) for 5 days each, and the metabolic profile was analysed every 24 h by LC/MS. The experiment was performed four times. The results of the four experiments are summarized in the following heatmaps. For clarity, only selected results are presented. The overall results are shown in the Supplements (Tables S1 and S2) for all experimental series. In addition, the results were compared with the results of a previous work in which the experiments were performed under proliferative conditions [20].




Figure 1. (**a**,**b**) Analysis of L929 cell proliferation under MetR. A total of 10,000 cells were seeded per well and incubated overnight. (**a**) Then, the cells were stimulated for 24, 72 and 120 h with or without methionine. The proliferation of the cells was analysed via ImageXpress digital microscopy analysis as described in the Materials and Methods. The figure shows one representative experiment (five values for every group). (**b**) The cells were incubated for 24, 48 and 72 h with a log2 dilution of methionine. The proliferation of the cells was analysed via ImageXpress digital microscopy analysis as described in the Materials and Methods. The figure shows one representative experiment (five values for every group). (**b**) The cells were incubated for 24, 48 and 72 h with a log2 dilution of methionine. The proliferation of the cells was analysed via ImageXpress digital microscopy analysis as described in the Materials and Methods. The figures show a summary of the results obtained from three independent experiments (two values for every group per experiment). Statistical analysis was performed using GraphPad Prism 5.0. Comparisons between Control and Met(–) groups were performed by applying one-way ANOVA followed by the Tukey–Kramer multiple comparison test (*** p < 0.001).

3.1. Under Full Medium, the Cells Replenish the Pool with All Amino Acids, but under MetR, Only Selected Amino Acids Are Added

In an analysis of the intracellular content of proteinogenic amino acids in full medium, for almost all amino acids, the highest concentration of 100% was reached after 120 h (Figure 2a). Basically, the cells replenish the amino acid pool despite contact inhibition. Even for amino acids that do not reach the maximum level (e.g., isoleucine and lysine), the level is kept as high as possible. The only exception was aspartate, and the value was

reduced from 96% after 48 h to 61%. This finding contrasts with the profile under MetR. Here, the values partly decreased (e.g., asparagine and glycine) or were kept at a low level (e.g., cysteine and threonine). However, individual amino acids may have a special role. In addition to aspartate, which was strongly consumed under full medium conditions, and arginine, which also had a high level under full medium, the amino acids lysine and tyrosine accumulated at maximum levels under MetR.

				со	nflu	ien	t									I	oro	life	rati	ive				
а	Compound	24 h	Cells in 48 h	Full N	edium 96 h	120 h	C 24 h	ells in f 48 h		Mediu	m 120 h		b	Compound	24 h	Cells in 48 h	Full M		120 h	0 24 h	ells in f 48 h	Net(-)	Mediu 96 h	
-	Alanine	89	84	98	100	100	70	^{48 n}	72 h	54	48		⊢	Alanine	66	84	88	98	100	56	48 1	72 h	29	27
	Arginine	62	90	91	87	98	85	80	86	85	100		L	Arginine	80	93	92	87	91	83	94	89	98	100
	Asparagine	79	78	90	100	97	64	44	32	37	33		L	Asparagine	80	98	85	94	100	74	43	33	39	35
	Aspartate	89	96	67	69	61	100	59	36	41	40		L	Aspartate	100	78	57	77	69	89	59	49	56	40
	Cysteine	63	91	77	94	100	56	60	56	64	57		L	Cysteine	77	81	87	91	100	82	63	72	85	80
	Glutamate	87	84	88	92	100	78	66	61	58	50		L	Glutamate	95	85	99	97	100	75	68	62	62	47
	Glutamine	66	59	78	86	100	64	54	55	64	70		L	Glutamine	47	70	81	93	100	59	56	73	84	81
	Glycine	73	89	84	99	100	74	63	43	43	34	la	L	Glycine	87	93	83	95	100	87	68	53	52	44
	Proline	100	94	93	98	99	84	68	55	54	51	cellul		Proline	96	100	79	91	90	94	61	52	55	41
Acids	Serine	64	57	74	76	100	62	45	58	62	75	<u>e</u>	loids	Serine	66	62	81	100	92	58	44	44	56	54
Amino A	Methionine	86	76	86	94	100	13	17	14	15	17	a	Amino Acids	Methionine	78	98	91	93	100	16	19	20	19	21
A	Histidine	81	81	80	91	100	87	79	67	76	78	ntra	Am	Histidine	75	100	85	97	97	80	70	53	63	55
	Isoleucine	82	68	68	58	71	100	88	78	85	82	-=	L	Isoleucine	79	100	81	85	80	84	81	69	80	76
	Leucine	86	69	72	65	84	100	91	79	93	91		L	Leucine	70	100	87	95	91	84	82	69	80	70
	Lysine	55	69	70	69	77	70	72	79	84	100		L	Lysine	63	70	78	73	72	66	79	88	96	100
		93	81	85	85	100	100	100	77	91	89		L		75	100	91	100	100	82	80	65	74	67
	Phenylalanine	79	84	85	94	100	78	70	64	71	79			Phenylalanine	80	93	89	95	100	73	67	54	64	64
	Threonine	95	82	84	81	99	100	100	72	86	82		L	Threonine	66	100	79	90	90	74	70	55	63	56
	Tryptophan	82	67	64	64	70	96			-			L	Tryptophan	83	100	86	89	88	90	92	81	91	93
	Tyrosine							100 81 100 93								30								
				-		-		and the second second		Contraction of the	-		L	Tyrosine					100	00		76		07
	Valine	78	75	83	91	100	86	78	69	80	93 77		L	l yrosine Valine	85	99	92	99	100	89	84	76	86	82
	Valine		75	-	91	-		78		80				Valine		99		99	100	89	84	76 (-) Me	86	82
С			75	83	91	-		78	69	80			d			99	92	99	100	89 24 h	84 Met		86 dium	82
с	Valine	78	75 Fu	83	91	100	86	78 Met	69 (-) Me	80 dium	77		d	Valine	85	99 Fu	92	99 um			84 Met	(-) Me 72 h	86 dium	
c	Valine Compound	78 24 h	75 Fu 48 h	83 I Medi 72 h	91 um 96 h	100	86 24 h	78 Met 48 h	69 (-) Me 72 h	80 dium 96 h	77 120 h		d	Valine Compound	85 24 h	99 Fu 48 h	92 I Medi 72 h	99 um 96 h	120 h	24 h	84 Met 48 h	(-) Me 72 h	86 dium 96 h	120 h
C	Valine Compound Alanine	78 24 h 35	75 Fu 48 h 57	83 Medi 72 h 46	91 96 h 29	100 120 h 23	86 24 h 37	78 Met 48 h 50	69 (-) Me 72 h 58	80 dium 96 h 69	77 120 h 79		d	Valine Compound Alanine	85 24 h 228	99 Fu 48 h 388	92 I Medi 72 h 478	99 um 96 h 505	120 h 414	24 h 159	84 Met 48 h 249	(-) Mee 72 h 306	86 dium 96 h 291	120 h 314
c	Valine Compound Alanine Arginine	78 24 h 35 34	Fu 48 h 57 63	83 Medi 72 h 46 67	91 96 h 29 67	120 h 23 61	86 24h 37 79	78 Met 48 h 50 87	69 (-) Me 72 h 58 90	80 dium 96 h 69 89	120 h 79 87		d	Valine Compound Alanine Arginine	85 24 h 228 87	99 Fu 48 h 388 97	92 Medi 72 h 478 99	99 um 96 h 505 99	120 h 414 93	24 h 159 95	84 48 h 249 100	(-) Me 72 h 306 104	86 ^{dium} 96 h 291 101	120 h 314 89
C	Valine Compound Alanine Arginine Asparagine	78 24 h 35 34 43	Fu 48 h 57 63 59	83 72 h 46 67 58	91 96 h 29 67 44	120 h 23 61 34	86 24 h 37 79 86	78 Met 48 h 50 87 92	69 (-) Me 72 h 58 90 95	80 dium 96 h 69 89 101	120 h 79 87 101		d	Valine Compound Alanine Arginine Asparagine	24 h 228 87 108	99 Fu 48 h 388 97 113	92 Medi 72 h 478 99 114	99 um 96 h 505 99 112	120 h 414 93 97	24 h 159 95 114	84 48 h 249 100 122	(-) Med 72 h 306 104 129	86 96 h 291 101 130	120 h 314 89 126
c	Valine Compound Alanine Arginine Asparagine Aspartate	78 24 h 35 34 43 31	75 Fu 48 h 57 63 59 37	83 Medi 72 h 46 67 58 39	91 96 h 29 67 44 39	120 h 23 61 34 36	86 24h 37 79 86 39	78 Met 48 h 50 87 92 44	(-) Me 72 h 58 90 95 48	80 dium 96 h 69 89 101 51	120 h 79 87 101 46		d	Valine Compound Alanine Arginine Asparagine Aspartate	24 h 228 87 108 104	99 Fu 48 h 388 97 113 118	92 Medi 72 h 478 99 114 119	99 96 h 505 99 112 123	120 h 414 93 97 124	24 h 159 95 114 115	84 48 h 249 100 122 128	(-) Mee 72 h 306 104 129 137	86 96 h 291 101 130 137	120 h 314 89 126 133
C	Valine Compound Alanine Arginine Asparagine Aspartate Cysteine	78 24 h 35 34 43 31 51	75 Fu 48 h 57 63 59 37 57	83 72 h 46 67 58 39 52	91 96 h 29 67 44 39 49	120 h 23 61 34 36 45	86 24 h 37 79 86 39 58	78 48 h 50 87 92 44 51	69 72 h 58 90 95 48 49	80 dium 96 h 69 89 101 51 50	77 120 h 79 87 101 46 49	ar	d	Valine Compound Alanine Arginine Asparagine Aspartate Cysteine	24 h 228 87 108 104 145	99 Fu 48 h 388 97 113 118 129	92 72 h 478 99 114 119 120	99 96 h 505 99 112 123 114	120 h 414 93 97 124 98	24 h 159 95 114 115 150	84 48 h 249 100 122 128 137	(-) Mee 72 h 306 104 129 137 131	86 96 h 291 101 130 137 128	120 h 314 89 126 133 121
C	Valine Compound Alanine Arginine Asparagine Aspartate Cysteine Glutamate	78 24 h 35 34 43 31 51 34	75 Fu 48 h 57 63 59 37 57 50	83 Medi 72 h 46 67 58 39 52 61	91 96 h 29 67 44 39 49 68	120 h 23 61 34 36 45 74	86 24h 37 79 86 39 58 41	78 48 h 50 87 92 44 51 52	 69 72 h 58 90 95 48 49 60 	80 96 h 69 89 101 51 50 67	77 120 h 79 87 101 46 49 64	ular	d	Valine Compound Alanine Arginine Asparagine Aspartate Cysteine Glutamate	24 h 228 87 108 104 145 132	99 Fu 48 h 388 97 113 118 129 178	92 Medi 72 h 478 99 114 119 120 226	99 96 h 505 99 112 123 114 232	120 h 414 93 97 124 98 274	24 h 159 95 114 115 150 142	84 48 h 249 100 122 128 137 184	(-) Mee 72 h 306 104 129 137 131 217	86 96 h 291 101 130 137 128 220	120 h 314 89 126 133 121 239
C .	Valine Compound Alanine Arginine Asparagine Asparate Cysteine Glutamate Glutamine	78 24h 35 34 43 31 51 34 107	75 Fu 48 h 57 63 59 37 57 50 65	83 72 h 46 67 58 39 52 61 16	91 96 h 29 67 44 39 49 68 17	120 h 23 61 34 36 45 74 20	86 24h 37 79 86 39 58 41 110	78 48 h 50 87 92 44 51 52 101	69 72 h 58 90 95 48 49 60 93	80 dium 96 h 69 89 101 51 50 67 89	120 h 79 87 101 46 49 64 83	Ы		Valine Compound Alanine Arginine Asparagine Aspartate Cysteine Glutamate Glutamine	24 h 228 87 108 104 145 132 83	99 Fu 48 h 388 97 113 118 129 178 67	92 72 h 478 99 114 119 120 226 38	99 96 h 505 99 112 123 114 232 27	120 h 414 93 97 124 98 274 21	24 h 159 95 114 115 150 142 105	84 48 h 249 100 122 128 137 184 99	(-) Mee 72 h 306 104 129 137 131 217 94	86 96 h 291 101 130 137 128 220 95	120 h 314 89 126 133 121 239 93
Acids	Valine Compound Alanine Arginine Asparagine Asparate Cysteine Glutamate Glutamine Glycine	78 24h 35 34 43 31 51 34 107 17	75 Fu 48 h 57 63 59 37 57 50 65 32	83 Medi 72 h 46 67 58 39 52 61 16 60	91 96 h 29 67 44 39 49 68 17 77	120 h 23 61 34 36 45 74 20 90	86 24h 37 79 86 39 58 41 110 21	78 Met 48 h 50 87 92 44 51 52 101 30	69 72 h 58 90 95 48 49 60 93 37	80 dium 96 h 69 89 101 51 50 67 89 44	77 120 h 79 87 101 46 49 64 83 46	cellul		Valine Compound Alanine Arginine Asparagine Aspartate Cysteine Glutamate Glutamine Glycine	24 h 228 87 108 104 145 132 83 136	99 Fu 48 h 388 97 113 118 129 178 67 209	92 Medi 72 h 478 99 114 119 120 226 38 292	99 96 h 505 99 112 123 114 232 27 338	120 h 414 93 97 124 98 274 21 494	24 h 159 95 114 115 150 142 105 149	84 48 h 249 100 122 128 137 184 99 223	(-) Mer 72h 306 104 129 137 131 217 94 273	86 96 h 291 101 130 137 128 220 95 274	120 h 314 89 126 133 121 239 93 309
nino Acids	Valine Compound Alanine Arginine Asparagine Aspartate Cysteine Glutamate Glutamine Glycine Proline	78 24h 35 34 43 31 51 34 107 17 31	75 Fu 48h 57 63 59 37 57 57 50 65 32 31	83 Medi 72h 46 67 58 39 52 61 16 60 26	91 96 h 29 67 44 39 68 17 77 20	120 h 23 61 34 36 45 74 20 90 17	86 24h 37 79 86 39 58 41 110 21 37	78 48h 50 87 92 44 51 52 101 30 41	69 72h 58 90 95 48 49 60 93 37 40	80 96 h 69 89 101 51 50 67 89 44 43	120 h 79 87 101 46 49 64 83 46 40	cellul		Valine Compound Alanine Arginine Asparagine Aspartate Cysteine Glutamate Glutamine Glycine Proline	24h 228 87 108 104 145 132 83 136 109	99 Ful 48 h 388 97 1113 118 129 178 67 209 98	92 72h 478 99 114 119 120 226 38 292 86	99 96 h 505 99 112 123 114 232 27 338 87	120 h 414 93 97 124 98 274 21 494 78	24 h 159 95 114 115 150 142 105 149 119	84 48h 249 100 122 128 137 184 99 223 128	(-) Me 72h 306 104 129 137 131 217 94 273 137	86 96 h 291 101 130 137 128 220 95 274 137	120 h 314 89 126 133 121 239 93 309 134
Amino Acids	Valine Compound Alanine Arginine Asparagine Asparate Cysteine Glutamate Glutamine Glycine Proline Serine	78 24h 35 34 43 31 51 34 107 17 31 18	75 Fu 48h 57 63 59 37 57 50 65 32 31 10	83 72h 46 67 58 39 52 61 16 60 26 11	91 96 h 29 67 44 39 68 17 77 20 9	120 h 23 61 34 36 45 74 20 90 17 90	86 24h 37 79 86 39 58 41 110 21 37 25	78 Mete 48 h 50 87 92 44 51 52 101 30 41 19	69 72h 58 90 95 48 49 60 93 37 40 19	80 96 h 69 89 101 51 50 67 89 44 43 22	120h 79 87 101 46 49 64 83 46 40 25	cellul	Amino Acids	Valine Compound Alanine Arginine Asparagine Aspartate Cysteine Glutamate Glutamate Glycine Proline Serine	24h 228 87 108 104 145 132 83 136 109 74	99 Fu 48 h 388 97 113 118 129 178 67 209 98 41	92 72h 478 99 114 119 120 226 38 292 86 20	99 96 h 505 99 112 123 114 232 27 338 87 24	120 h 414 93 97 124 98 274 21 494 78 28	24h 159 95 114 115 150 142 149 119 81 69	84 Met 48 h 249 100 122 128 137 184 99 223 128 68 38	(-) Mee 72h 306 104 129 137 131 217 94 273 137 64	86 ^{96 h} 2911 101 130 137 128 220 95 274 137 76	120 h 314 89 126 133 121 239 93 309 134 78 14
Amino Acids	Valine Compound Alanine Arginine Asparagine Asparagine Asparate Cysteine Glutamate Glutamine Glutamine Glycine Proline Serine Methionine Histidine	78 24h 35 34 43 31 51 34 107 17 31 18 49 17	75 Fu 48 h 57 63 59 37 57 57 57 57 57 65 32 31 10 34 19	83 72h 46 67 58 39 52 61 16 60 26 11 18 18	91 96 h 29 67 44 39 49 68 17 77 20 9 11 17	120 h 23 61 34 36 45 74 20 90 17 90 17 9	86 24h 37 79 86 39 58 41 110 21 37 25 10 22	78 48h 50 87 92 44 51 52 101 30 41 19 6 25	 69 72h 58 90 95 48 49 60 93 37 40 19 4 27 	80 dium 96 h 69 89 101 51 50 67 89 44 43 22 30	777 120h 79 87 101 46 49 64 83 46 40 25 5 31	Ы		Valine Compound Alanine Arginine Asparagine Aspartate Cysteine Glutamate Glutamine Glycine Proline Serine Methionine Histidine	24h 228 87 108 104 145 132 83 136 109 74 86 111	99 Fu 48 h 388 97 113 118 129 178 67 209 98 41 71 113	92 72h 478 99 114 119 120 226 38 292 86 20 46 99	99 96 h 505 99 112 123 114 232 27 338 87 24 41 100	120 h 414 93 97 124 98 274 21 494 78 28 17 92	24h 159 95 114 115 150 142 105 149 119 81 69	84 Met 48 h 249 100 122 128 137 184 99 223 128 68 38 139	(-) Meer 72h 306 104 129 137 131 217 94 273 137 64 222 150	86 96 h 291 101 130 137 128 220 95 274 137 76 18 156	120 h 314 89 126 133 121 239 93 309 134 78 14 151
Amino Acids	Valine Compound Alanine Arginine Asparagine Asparagine Glytamate Glytamate Glytamate Glytame Serine Methionine Histidine Isoleucine	78 24h 35 34 43 31 51 34 107 17 31 18 49 17 49	75 Fu 48h 57 63 59 37 50 65 32 31 10 34 19 35	83 72h 46 67 58 39 52 61 16 60 26 11 18 18 18	91 96h 29 67 44 39 68 17 77 20 9 11 17 5	120 h 23 61 34 36 45 74 20 90 17 90 17 9 7 18 4	86 24h 37 79 86 39 58 41 110 21 37 25 10 22 56	78 Met 48 h 50 87 92 44 51 52 101 30 41 19 6 25 56	69 72 h 72 h 58 90 95 48 49 60 93 37 40 19 4 27 55	80 dium 96 h 69 89 101 51 50 67 89 44 43 22 3 30 58	120h 79 87 101 46 49 64 83 46 40 25 5 31 54	cellul		Valine Compound Alanine Arginine Asparagine Aspartate Cysteine Glutamate Glutamine Glycine Proline Serine Methionine Histidine Isoleucine	24h 228 87 108 104 145 132 83 136 109 74 86 1111 79	99 Fui 388 97 113 118 129 178 67 209 98 41 71 113 68	92 72h 478 99 114 119 120 226 38 292 86 20 46 99 50	99 96h 505 99 112 123 114 232 27 338 87 24 41 1000 44	120 h 414 93 97 124 98 274 21 494 78 28 17 92 20	24h 159 95 114 115 150 142 149 119 81 69 126 90	84 Met 48 h 249 100 122 128 137 184 99 223 128 68 38 139 89	(-) Meer 72h 306 104 129 137 131 217 94 273 137 64 22 150 93	86 96 h 291 101 130 137 220 95 274 137 76 18 156 98	120 h 314 89 126 133 121 239 93 309 134 78 14 151 101
Amino Acids	Valine Compound Alanine Arginine Asparagine Asparate Cysteine Glutamate Glutamine Glycine Proline Serine Methionine Histidine Isoleucine Leucine	78 24h 35 34 43 31 51 34 107 17 31 18 49 17 49 37	75 Fu 48h 57 63 59 37 57 50 65 32 31 10 34 19 35 23	83 72h 46 67 58 39 52 61 16 60 26 11 18 18 18 11 7	91 96h 29 67 44 39 68 17 77 20 9 11 17 5 3	120h 23 61 34 36 45 74 20 90 17 90 7 17 9 7 18 4 3	244h 37 79 86 39 58 41 110 21 37 25 10 22 56 43	78 48h 50 87 92 44 51 52 101 30 41 19 6 25 56 48	69 72h 58 90 95 48 49 60 93 37 40 19 40 19 4 27 55 55 49	80 96 h 69 89 101 51 51 51 51 67 89 44 43 22 3 30 58 55	120h 79 87 101 46 49 64 83 46 40 25 5 31 54 54 50	cellul		Valine Compound Alanine Arginine Asparagine Aspartate Cysteine Glutamate Glutamate Glycine Proline Serine Methionine Histidine Isoleucine Leucine	24h 228 87 108 104 145 132 83 136 109 74 86 111 79 87	99 Fui 48h 388 97 113 118 129 178 67 209 98 41 71 113 68 77	92 92 72h 478 99 114 119 120 226 38 292 26 38 292 86 20 46 99 50 50	99 96 h 505 99 112 123 114 232 27 338 87 24 41 100 44 43	120 h 414 93 97 124 98 274 21 494 78 28 17 92 20 18	24h 159 95 114 115 150 149 119 81 69 126 90 106	84 48h 249 100 122 128 137 184 99 223 128 68 38 139 89 104	(-) Mee 72h 306 104 129 137 131 217 94 273 137 64 22 150 93 112	86 96 h 291 101 130 137 128 220 95 274 137 76 18 156 98 126	120 h 314 89 126 133 121 239 93 309 134 78 14 151 101 128
Amino Acids	Valine Compound Alanine Arginine Asparagine Asparagine Glutamate Glutamate Glutamine Glycine Proline Serine Methionine Histidine Isoleucine Leucine Lysine	78 24h 35 34 43 31 51 34 107 17 31 18 49 17 49 37 15	75 Fu 48h 57 63 59 37 57 57 57 50 65 32 31 10 34 19 35 23 24	83 72h 46 67 58 39 52 61 16 60 26 11 18 18 18 18 11 7 22	91 96h 29 67 44 39 68 17 77 20 9 11 17 5 3 3 21	120h 23 61 34 36 45 74 20 90 17 90 17 9 7 18 4 3 19	86 24h 37 79 86 39 58 41 110 21 37 25 10 22 56 43 25	78 48h 50 87 92 44 51 51 52 101 30 41 19 6 25 56 48 27	69 72 h 58 90 95 48 49 60 93 37 40 19 40 19 4 27 55 49 27	80 96 h 69 89 101 51 50 67 89 44 43 22 30 58 55 26	777 120h 79 87 101 46 49 64 83 46 40 25 5 31 54 50 30	cellul		Valine Compound Alanine Arginine Asparagine Aspartate Cysteine Glutamate Glutamate Glycine Proline Solycine Histidine Isoleucine Leucine Lysine	24h 228 87 108 104 145 132 83 136 109 74 86 111 79 87 74	99 Fui 48h 388 97 113 118 129 178 67 209 98 41 71 113 68 77 70	92 72h 478 99 114 119 120 226 38 292 86 20 46 99 50 50 50 57	99 96 h 505 99 112 123 114 232 27 338 87 24 41 100 44 43 55	120 h 414 93 97 124 98 274 21 494 78 28 17 92 20 18 47	24h 159 95 114 115 150 142 105 149 119 81 69 126 90 106 84	84 48 h 249 100 122 128 137 184 99 223 128 68 38 139 89 104 84	(-) Mee 72h 306 104 129 137 131 217 94 273 137 64 22 150 93 112 78	86 96 h 291 101 130 137 128 220 95 274 137 76 18 156 98 126 77	120h 314 89 126 133 121 239 93 309 134 78 14 151 101 128 64
Amino Acids	Valine Compound Alanine Arginine Asparagine Asparate Cysteine Glutamate Glutamine Glycine Proline Serine Methionine Histidine Isoleucine Leucine Lysine Phenylalanine	78 24h 35 34 43 31 51 34 107 17 31 18 49 17 49 37 15 28	75 Fu 48h 57 63 59 37 57 50 65 32 31 10 34 19 35 23 24 19	83 Media 72h 46 67 58 39 52 61 16 60 26 11 18 18 18 18 11 7 7 22 12	91 96 h 29 67 44 39 68 17 77 20 9 11 17 5 3 3 21 8	100 120 h 23 61 34 36 45 74 20 90 17 90 7 18 4 3 19 9 9 9 9	86 24h 37 79 86 39 58 41 110 21 37 25 10 22 56 43 25 31	78 Met 48 h 50 87 92 44 51 52 101 30 41 19 6 25 56 48 27 38	69 72 h 58 90 95 48 49 60 93 37 40 19 4 27 55 49 27 41	80 dium 96 h 69 89 101 51 50 67 89 44 43 22 30 58 55 26 46	120h 79 87 101 46 49 64 83 46 40 25 5 31 54 50 30 45	cellul		Valine Compound Alanine Arginine Arginine Asparagine Asparate Gysteine Glutamate Glutamate Glycine Proline Methionine Histidine Isoleucine Leucine Leucine Phenylalanine	85 24h 228 87 108 104 145 132 83 136 109 74 86 1111 79 87 74 98	99 Fui 48 h 388 97 113 118 129 178 67 209 98 41 71 113 68 77 70 87	92 92 72h 478 99 114 119 120 226 38 292 38 292 20 46 99 50 50 50 57 58	99 96 h 5055 99 112 123 114 232 27 338 87 24 41 100 44 43 55 56	120 h 414 93 97 124 98 274 21 494 78 28 17 92 20 18 47 34	24h 159 95 114 115 142 149 119 81 69 126 90 106 84 120	84 48 h 249 100 122 128 137 184 99 223 128 68 38 139 89 104 84 134	(-) Mee 72h 306 104 129 137 131 217 94 273 137 64 22 150 93 112 78 150	86 dium 96 h 2911 1011 1300 1377 128 2200 95 2744 1377 76 18 156 98 1266 77 163	120 h 314 89 126 133 121 239 93 309 134 78 14 151 101 128 64 175
Amino Acids	Valine Compound Alanine Arginine Asparagine Asparate Cysteine Glutamate Glutamate Glutamine Glycine Proline Serine Methionine Histidine Isoleucine Leucine Leucine Phenylalanine Threonine	78 24h 35 34 43 31 51 34 107 17 31 18 49 17 49 37 15 28 16	75 Fu 48h 57 63 59 37 50 65 32 31 10 34 19 35 23 24 19 18	83 Media 72h 46 67 58 39 52 61 16 60 26 11 18 18 18 11 7 7 22 12 18	91 96 h 29 67 44 39 49 68 17 77 20 9 11 17 5 3 3 21 8 8 14	100 120 h 23 61 34 36 45 74 20 90 17 90 77 18 4 3 19 9 9 12	86 24h 37 79 86 39 58 41 1100 21 37 25 100 22 56 43 25 31 22	78 48h 50 87 92 44 51 52 101 30 41 19 6 25 56 48 27 38 24	69 72 h 58 90 95 48 49 60 93 37 40 19 4 27 45 49 60 93 37 40 19 4 27 41 26	80 dium 96 h 69 89 101 51 50 67 89 44 43 22 30 58 30 58 55 26 46 29	120h 79 87 101 46 49 64 83 46 40 25 5 31 54 55 31 54 50 30 45 30	cellul		Valine Compound Alanine Arginine Arginine Asparagine Asparate Cysteine Glutamate Glutamate Glutamine Glycine Proline Histidine Isoleucine Leucine Leucine Phenylalanine Threonine	85 24h 228 87 108 104 145 132 83 136 109 74 86 1111 79 87 74 98 81	99 Fui 48 h 388 97 113 118 129 178 67 209 98 41 71 113 68 77 70 87 79	92 92 72h 478 99 114 119 120 226 38 292 26 38 292 20 46 99 50 50 50 57 58 68	99 96h 505 99 112 123 114 232 27 338 87 24 41 100 44 43 55 56 71	120 h 414 93 97 124 98 274 21 494 21 494 78 28 17 92 20 18 47 34 54	24h 159 95 114 115 150 142 105 149 119 81 69 126 90 106 84 120 93	84 48 h 2499 1000 1222 128 137 184 99 2233 128 68 38 139 89 104 84 134 101	(-) Mee 72h 306 104 129 137 131 217 94 273 137 64 22 150 93 112 78 150 111	86 dium 96 h 2911 1011 1300 1377 128 2200 95 2774 1377 76 18 156 98 1266 77 1633 1177	120 h 314 89 126 133 121 239 93 309 134 78 14 151 101 128 64 175 117
Amino Acids	Valine Compound Alanine Arginine Asparagine Asparate Cysteine Glutamate Glutamate Glutamine Glycine Proline Serine Methionine Histidine Isoleucine Leucine Leucine Lysine Phenylalanine Threonine Tryptophan	78 24h 35 34 43 31 51 34 107 17 31 18 49 17 49 37 15 28 16 225	75 Fu 48h 57 63 59 37 57 50 65 32 31 10 34 19 35 23 24 19 18 139	83 Medi 72h 46 67 58 39 52 61 16 60 26 11 18 18 18 11 7 7 222 12 12 18 78	91 96 h 29 67 44 39 49 68 17 77 20 9 11 17 5 3 21 8 14 44	100 120 h 23 61 34 36 45 74 20 90 17 90 7 7 18 4 3 3 19 9 9 12 30	86 24h 37 79 86 39 58 41 110 21 37 25 10 22 56 43 25 31 22 90	78 Met 48 h 50 87 92 44 51 52 101 30 41 19 6 25 56 48 27 38 24 135	69 72 h 58 90 95 48 49 60 93 37 40 19 4 27 55 49 27 41 26 139	80 dium 96 h 69 89 101 51 50 67 89 44 43 22 30 58 55 26 46 29 155	120h 79 87 101 46 49 64 83 46 40 25 5 31 54 55 31 54 50 30 45 30 137	cellul		Valine Compound Alanine Arginine Arginine Asparagine Asparate Cysteine Glutamate Glutamate Glutamine Glycine Proline Serine Methionine Histodine Isoleucine Leucine Leucine Phenylalanine Threonine Tryptophan	85 24h 228 87 108 87 108 145 132 83 136 109 74 86 1111 79 87 74 98 81 81 84	99 Fui 48 h 388 97 113 118 129 178 67 209 98 41 71 113 68 77 70 87 79 72	92 72 h 99 114 119 120 226 38 292 86 20 46 99 50 50 50 50 57 58 68 49	99 96h 505 99 112 123 114 232 27 338 87 24 41 100 44 43 55 55 56 71 44	120 h 414 93 97 124 98 274 21 494 21 494 78 28 17 92 20 18 47 34 54 54 26	24h 159 95 114 115 150 142 105 149 119 81 69 126 90 106 84 120 93 107	84 48 h 2499 1000 1222 128 137 184 99 2233 128 68 38 139 89 104 84 134 101 115	(-) Mee 72h 306 104 129 137 131 217 94 273 137 64 22 150 93 112 78 150 111 126	86 96 h 291 101 130 137 128 220 95 274 137 76 18 126 98 1266 98 1266 77 163 117 132	120 h 314 89 126 133 121 239 93 309 134 78 14 151 101 128 64 175 117 143
Amino Acids	Valine Compound Alanine Arginine Asparagine Asparate Cysteine Glutamate Glutamate Glutamine Glycine Proline Serine Methionine Histidine Isoleucine Leucine Leucine Phenylalanine Threonine	78 24h 35 34 43 31 51 34 107 17 31 18 49 17 49 37 15 28 16	75 Fu 48h 57 63 59 37 50 65 32 31 10 34 19 35 23 24 19 18	83 Media 72h 46 67 58 39 52 61 16 60 26 11 18 18 18 11 7 7 22 12 18	91 96 h 29 67 44 39 49 68 17 77 20 9 11 17 5 3 3 21 8 8 14	100 120 h 23 61 34 36 45 74 20 90 17 90 77 18 4 3 19 9 9 12	86 24h 37 79 86 39 58 41 1100 21 37 25 100 22 56 43 25 31 22	78 48h 50 87 92 44 51 52 101 30 41 19 6 25 56 48 27 38 24	69 72 h 58 90 95 48 49 60 93 37 40 19 4 27 45 49 60 93 37 40 19 4 27 41 26	80 dium 96 h 69 89 101 51 50 67 89 44 43 22 30 58 30 58 55 26 46 29	120h 79 87 101 46 49 64 83 46 40 25 5 31 54 55 31 54 50 30 45 30	cellul		Valine Compound Alanine Arginine Arginine Asparagine Asparate Cysteine Glutamate Glutamate Glutamine Glycine Proline Histidine Isoleucine Leucine Leucine Phenylalanine Threonine	85 24h 228 87 108 104 145 132 83 136 109 74 86 1111 79 87 74 98 81	99 Fui 48 h 388 97 113 118 129 178 67 209 98 41 71 113 68 77 70 87 79	92 92 72h 478 99 114 119 120 226 38 292 26 38 292 20 46 99 50 50 50 57 58 68	99 96h 505 99 112 123 114 232 27 338 87 24 41 100 44 43 55 56 71	120 h 414 93 97 124 98 274 21 494 21 494 78 28 17 92 20 18 47 34 54	24h 159 95 114 115 150 142 105 149 119 81 69 126 90 106 84 120 93	84 48 h 2499 1000 1222 128 137 184 99 2233 128 68 38 139 89 104 84 134 101	(-) Mee 72h 306 104 129 137 131 217 94 273 137 64 22 150 93 112 78 150 111	86 dium 96 h 2911 1011 1300 1377 128 2200 95 2774 1377 76 18 156 98 1266 77 1633 1177	120 h 314 89 126 133 121 239 93 309 134 78 14 151 101 128 64 175 117

Figure 2. (**a**–**d**) Relative amounts of proteinogenic amino acids under MetR comparing confluent and proliferative conditions with the cell line L929. The metabolism of the murine cell line L929 was analysed in full medium and MetR under both confluent (**a**,**c**) and proliferative conditions (**b**,**d**) over a period of 5 days. For each day of the experiment, the preparation was performed in triplicate. After 24, 48, 72, 96 and 120 h, both the medium (extracellular) and the cell lysates (intracellular) were analysed by LC/MS. The results were reproduced in four independent experiments and finally summarized. In this figure, the results of the proteinogenic amino acids are shown. For the values of the media, the control measurement of the medium used was defined as 100%. For the cell pellets, the highest measured value in each test series was defined as 100%.

In a comparison of the intracellular profile under confluent conditions with that under proliferative conditions (Figure 2b), the common tendencies are striking and are almost identical over large areas. Under full medium, the cells refuelled the amino acid pool, whereas under MetR, the cells largely abstained from amino acid uptake. However, under both proliferative and confluent conditions, the amino acids arginine, lysine, and tyrosine were more important, as they were basically present at very high levels, than the other amino acids and were even taken up by the cells. These amino acids may play a special role in the LEM under MetR.

Similar observations were found when comparing the profiles of extracellular concentrations in the medium. Under full medium, the amino acid content in the medium decreased for the majority of amino acids, while it increased under MetR for many amino acids. Although the cells under MetR still took up amino acids at the beginning, which was especially obvious after 24 h under confluent conditions, as time increased, many amino acids remained at a relatively constant level, indicating a stagnant or balanced amino acid import. The obvious exceptions were some amino acids that are strongly secreted (e.g., glycine); however, these amino acids were secreted under all conditions and thus likely have important functions in general, independent of proliferation and methionine content. Only the concentrations varied in the different conditions. As an example, glutamate was secreted to a fairly similar extent under all conditions. Alanine had a different pattern. While alanine was strongly secreted under the other conditions, the content decreased to a low value (23%) under confluent conditions in the full medium.

3.2. Substance Classes and Metabolic Pathways

In addition to the importance of the relative concentration of individual molecules, the summed relative masses of all relevant metabolites belonging to one pathway (e.g., the urea cycle) provide relevant information about its overall regulation. This type of analysis was performed for amino acids (except methionine), the urea cycle, the TCA cycle, carbohydrates, pyrimidines, and purines in both media and cell extracts under confluent and proliferative conditions (Figure 3a–d).

For the group of extracellular amino acids, the results already described can also be shown in total (Figure 3a,b). While the amino acid content decreased under full medium, it increased, albeit only slightly under MetR, under both confluent and proliferative conditions. The metabolic pathways of urea and the TCA cycle and the classes of pyrimidines and purines showed similar trends under all extracellular conditions and differed only in intensity. In contrast, the class of carbohydrates is an exception. Under proliferative conditions, the secreted amounts increased strongly, whereas under confluent conditions, probably also due to the much higher cell number, both under full medium and MetR, the sum of metabolites decreased drastically at the beginning. Under MetR, however, the trend towards increased secretion was again observed; under confluent conditions, the secretion in the full medium slowly stagnated and even decreased further to below the initial value after 24 h at the end.

Intracellularly, the sums of amino acids were consistent with the previous results. While the concentration increased under full medium and was maintained at a high level, the values decreased under MetR or remained at a constant level under both confluent and proliferative conditions. All other groups showed heterogeneous results overall. Thus, metabolites remain at rather high levels under full medium and increase under proliferative conditions, whereas they tend to decrease under MetR. Similar results were found for the TCA cycle. For the groups of carbohydrates, pyrimidines, and purines, the levels decreased under proliferative conditions and MetR, whereas the decrease was less pronounced or remained constant under confluent conditions. Under full medium, the opposite pattern was observed. Here, the concentrations in the three groups mentioned above increased or remained constant under proliferative conditions until the end of the experiment. The carbohydrates showed a cyclic pattern, always showing a temporal decrease followed by an increase.

			СО	nflu	ent	t –						proliferative											
-		Ful	l Med	ium			Met	(-) Me	dium			h		Fu	l Med	ium			Met	:(-) Me	dium		
а	24 h	48 h	72 h	96 h	120 h	24 h	48 h	72 h	96 h	120 h	L .	b	24 h	48 h	72 h	96 h	120 h	24 h	48 h	72 h	96 h	120 h	Ι.
Amino Acids	36	36	28	26	26	45	48	50	53	51	Ila	Amino Acids	92	94	82	80	72	105	111	116	118	114	-
Urea Cycle	17	24	26	26	23	19	25	26	28	29	ן בו	Urea Cycle	86	87	101	117	108	73	100	117	139	137	=
TCA Cycle	41	52	66	95	131	50	53	66	88	112	Se l	TCA Cycle	147	141	163	178	210	129	137	151	153	173	
Carbohydrates	38	47	57	42	25	36	34	42	70	94	extracellula	Carbohydrates	232	395	475	570	645	225	257	274	304	427	60 Õ
Pyrimidines	27	30	38	45	53	27	32	38	46	80	6	Pyrimidines	94	117	139	138	161	106	121	150	157	160	
Purines	20	23	26	34	41	22	27	38	63	90		Purines	52	62	67	72	82	54	61	81	91	142	
		Cellsir	Full N	/lediur	n	Cells in Met(-) Medium								Cellsir	Full N	lediur	n	C	ells in I	Met(-)	Mediu	ım	Γ
С	24 h	Cells in 48 h	72 h		n 120 h				120000000000000000000000000000000000000	um 120 h		d	24 h	Cells ir 48 h			n 120 h		ells in l 48 h			ım 120 h	
-					No. of Concession, Name		1		11		<u> </u>						-	No. of Concession, Name	10000000	(Second)	1		
Amino Acids	86	81	86	90	100		76	66	74	73	E I	Amino Acids	82	99	90	99	100		72	64	72	65	
Urea Cycle	98	89	82	83	96	100	72	74	76	88		Urea Cycle	78	100	90	98	87	87	79	66	78	75	
TCA Cycle	73	85	73	74	80	100	69	80	71	83	ace	TCA Cycle	66	98	88	100	77	68	82	62	74	62	
Carbohydrates	81	60	61	56	75	100	72	89	82	98	intracellula	Carbohydrates	76	100	75	92	73	79	86	73	75	65	a hard a second s
	82	80	85	86	90	100	91	79	79	63	.	Pyrimidines	100	81	68	89	68	98	81	60	67	46	•
Pyrimidines	02												OF	02	88	00	100	OF	00				
Pyrimidines Purines	68	72	74	95	97	80	100	95	100	77		Purines	95	82	00	96	100	95	83	84	80	61	
		72	74	95	97	80	100	95	100	77		Purines	32	82	00	96	100	95	83	84	80	61	

Figure 3. (**a**–**d**) Overview of individual metabolic classes and metabolic groups under MetR in a comparison between confluent and proliferative conditions in the cell line L929. The metabolism of the murine cell line L929 was analysed in full medium and MetR under both confluent (**a**,**c**) and proliferative conditions (**b**,**d**) over a period of 5 days. For each day of the experiment, the preparation was performed in triplicate. After 24, 48, 72, 96 and 120 h, both the medium (extracellular) and the cell lysates (intracellular) were analysed by LC/MS. The results were reproduced in four independent experiments and finally summarised. This figure shows the results of selected classes of substances and metabolic pathways. For the values of the media, the control measurement of the medium used was defined as 100%. For the cell pellets, the highest measured value in each test series was defined as 100%.

3.3. MetR Induces LEM in L929 Cells at the Metabolic Level and Is Essentially Independent of *Proliferation and Contact Inhibition*

That the LEM is a program that is more or less independent of proliferation or contact inhibition is particularly evident from the so-called metabolic footprint, a selected group of metabolites. In a previous work, we defined the metabolic footprint as specific to the LEM under MetR, as these products either reflected appropriate biological activity and/or exhibited extreme differences under the conditions. The selected molecules were ATP, acetoacetate, creatine, spermidine, GSSG (glutathione in the oxidized form), UDP-glucose, and pantothenate. Thus, ATP is an ideal indicator of energy levels due to its biological function. Spermidine, for example, indicates high energy metabolism in cells when present at high concentrations and can inhibit proliferation when present at low concentrations or induce autophagy when taken up extracellularly, thus reflecting important indicators of restriction by its concentration [28,29]. The footprint should be used in studies to identify LEM as quickly as possible, even with alternative measurement methods (ELISA, Western blot, etc.), and is thus independent of costly mass spectrometry. Therefore, caloric restriction mimetics (e.g., metformin or rapamycin) [30,31] can be analysed in L929 cells or agents potentially capable of inducing CR via alternative pathways.

For this reason, the analysis of the metabolome under confluent conditions is also a quality control of whether the metabolite group we defined is suitable as a marker. When we compared the footprint under confluent and proliferative conditions (Figure 4a,b), we found that the metabolic profiles tended to be almost identical in a broad range of areas and are characteristic of MetR and full medium, respectively. The ATP content

sharply decreased under MetR at a very early time point, whereas the concentration of acetoacetate increased continuously. The percentage trend for creatine was almost identical, increasing continuously in full medium and decreasing continuously under MetR, regardless of proliferation or confluence. Spermidine, as an activity marker, remained at a very high level under full medium, whereas due to the lower energy balance under MetR, spermidine content continuously decreased. GSSG, the oxidized form of glutathione, also increased independently of proliferation in full medium, while under MetR, the concentration remained low. The opposite result was found for UDP-glucose. Finally, panthotenate showed a constantly high level under full medium but a significantly lower content under MetR.

	confluent											proliferative												
-		Cells in	n Full f	Mediun	n	Ce	Cells in Met(-) Medium					l.		Cells i	n Full N	/lediun	n	0	Cells in Met(-) Medium					
а	24 h	48 h	72 h	96 h	120 h	24 h	48 h	72 h	96 h	120 h	D	24 h	48 h	72 h	96 h	120 h	24 h	48 h	72 h	96 h	120 h			
ATP	100	68	28	35	37	20	6	8	13	19		ATP	100	89	61	49	23	47	13	7	6	7		
Acetoacetate	44	31	30	27	36	74	67	59	91	100		Acetoacetate	65	77	66	65	61	61	81	85	100	97		
Creatine	58	72	83	96	100	68	65	54	52	41		Creatine	52	68	68	100	96	66	66	52	53	40		
Spermidine	94	94	95	100	100	97	94	72	68	51		Spermidine	95	94	90	100	98	92	78	66	57	39		
GSSG	18	28	46	78	100	19	20	18	19	17		GSSG	16	27	33	62	100	20	17	18	17	11		
UDP-Glucose	36	11	14	9	13	100	70	52	76	71		UDP-Glucose	53	77	35	17	12	58	84	69	100	92		
Pantothenate	84	87	80	100	98	64	49	53	60	69		Pantothenate	63	84	79	100	94	48	37	36	41	37		
	0	10	20	35	50	60	70	80	90	100			0	10	20	35	50	60	70	80	90	100		

Figure 4. (**a**,**b**) Metabolic footprints of the cell line L929. The metabolism of the murine cell line L929 was analysed in full medium and MetR under both confluent (**a**) and proliferative conditions (**b**) over a period of 5 days. For each day of the experiment, the preparation was performed in triplicate. After 24, 48, 72, 96 and 120 h, the cell lysates (intracellular) were analysed by LC/MS. The results were reproduced in four independent experiments and finally summarised. This figure shows the results of the intracellular metabolites used to define the metabolic footprint for LEM. For the cell pellets, the highest measured value in each test series was defined as 100%.

4. Discussion

In general, the different forms of restriction in both cells and organisms show many similarities at the molecular and metabolic levels, which usually lead to an extension of the lifespan over a long period of time as well as to the prevention of classic age-associated diseases such as type II diabetes, cardiovascular diseases, and cancer. MetR is a suitable method to generally investigate the effects and relevance of amino acid restriction in cells and organisms. In a previous work, we showed that MetR leads to the induction of LEM in the murine cell line L929 at the metabolic level. We used LC/MS to define both a comprehensive fingerprint and a footprint comprising only a few metabolites, which is sufficient to analyse and define MetR.

In this work, we investigated the extent to which contact inhibition affects the metabolism of L929 cells and whether inhibition of proliferation induces a metabolic profile equivalent to that of an LEM. We cultured L929 cells under confluent conditions using full medium and MetR for a period of 5 days and analysed the profile of more than 150 metabolites every 24 h by LC/MS. In addition, the profiles were compared with the metabolic profiles of cells under proliferative conditions from the previous work mentioned above [20].

Interestingly, the cells retained their characteristic profile independent of proliferation or confluence. In principle, proliferation and contact inhibition have a slight influence on the metabolic profile, but the determining factor is whether it is full medium or MetR. Under full medium, cells showed a tendency to maintain active and energetic metabolism to be ready for optional proliferation at any time point. In contrast, MetR induced metabolism equivalent to that of an LEM under both proliferative and confluent conditions. This phenomenon is particularly evident from the comparison of footprints under confluent and proliferative conditions, which are nearly identical (Figure 4a,b). These results are important, as they demonstrate the possibility of inducing cells to develop LEM in principle and at any time point. In general, chemical systems are very complex and can be influenced by a multitude of external factors that lead to special and situation-specific reactions under stress conditions [32]. However, we assume that the LEM is an intrinsic program that is already established in unicellular organisms and strongly conserved in evolution. The cross-species involvement of mTOR and the sirtuins in the regulation of LEM are examples [11,14].

This finding may be important for cancer therapy. Longo and colleagues showed in a series of studies that prolonged restriction is necessary, but that short-term fasting (no calorie intake) or fasting-mimicking diets (FMDs) lead to varied alterations in growth factors and in metabolite levels, generating environments that can reduce the ability of cancer cells to adapt and survive, and thus improving the effects of cancer therapies. In addition, fasting or FMDs increased resistance to chemotherapy in normal but not cancer cells and promoted regeneration in normal tissues, which could help prevent detrimental and potentially life-threatening side effects of treatments [33]. This result is in extreme contrast to frequent recommendations, e.g., by the American Cancer Society, to increase calorie and protein intake in cancer patients [34]. In mammals, as well as humans, fasting leads to cell protection. The protective effect is mediated by, among other things, a strong reduction in the growth factor IGF-1. In addition, fasting-induced proto-oncogenes act as important negative regulators. This result further leads to an extreme situation called "differential stress resistance". Cancer cells expressing oncogenes themselves and with egocentric proliferative behaviour essentially respond to selected cancer-promoting and growth factors. Thus, cancer cells also do not respond to the protective signals generated by fasting in the short term or by restrictions in the long term. For this reason, the cells are in two extreme situations: somatic cells are protected, while cancer cells become additionally vulnerable to attack [35]. This phenomenon is especially true when cancer cells do not limit proliferation due to restriction but maintain their high energy and thus proliferative mode.

A good example is the use of cisplatin in combination with fasting. Short-term starvation (STS) based on calorie and/or protein reduction protects normal cells while simultaneously sensitizing malignant cells to high-dose chemotherapeutic drugs such as cisplatin in mice and possibly patients. The fasting-dependent protection of normal cells and sensitization of malignant cells depend, in part, on reduced levels of IGF-1 and glucose [36]. However, success against cancer is tumour dependent. While glioma progression could not be delayed in mouse models [36], work on cisplatin-resistant non-small human cell lung cancer and ovarian cancer cell lines showed that cisplatin-resistant clones were more sensitive to killing by nutrient deprivation in vitro and in vivo. Mass spectrometry revealed glutamine as central for nucleotide biosynthesis rather than for anaplerotic and bioenergetic reactions in cisplatin-resistant cells. Glutamine depletion was sufficient to restore the cisplatin responses of initially cisplatin-resistant cells [30,37].

Additionally, in this work, it was shown under both proliferative and confluent conditions that amino acids represent an ideal target, which is why they have become increasingly important in tumour therapy over the last decade [38,39]. The central role is based, among other things, on the fact that the essential mass of proliferating cells is generated from extracellularly absorbed amino acids [5]. As already mentioned, glutamine, among others, plays an important role here, as glutamine is the extracellular transport amino acid par excellence and can thus replenish the citrate cycle intracellularly distributed via the blood by means of glutaminolysis but also plays a role in other biological processes, such as nucleotide synthesis [40].

Based on the results of LC/MS under proliferative and confluent conditions in MetR, two relevant aspects are notable. A large portion of the amino acids are barely taken up intracellularly or even secreted into the medium, thus playing only a minor role in the LEM status of the cell. Other amino acids continue to be absorbed or stored to a greater extent under MetR. However, the question arises to what extent the cell truly needs these in the LEM or whether a reserve is not simply created for better, i.e., highly proliferative conditions. Regardless of the loading status of the amino acids, under LEM conditions, they are only needed to a much lesser extent or at a later time point. These results are in contrast to the tumour, reflected in part in this work by the full medium conditions, which permanently tries to remain in high energy mode and is thus prepared for optional proliferation.

It is precisely for this reason that the tumour is extremely vulnerable to attack. If the amino acid supply is inhibited, e.g., by using an amino acid transport inhibitor or an inhibitor of glutaminolysis, this will essentially affect the tumour but not the frugal and nonproliferating cells in LEM mode. A possible candidate would be V9302, which is also already successfully used in clinical trials, and glutaminolysis inhibitors [41,42].

How effective protein restriction can be in preventing tumours has already been shown by Levine and colleagues, both in a human study and in in vivo experiments in mouse models [43]. How successful would a combination of restriction and various amino acid inhibitors be? It remains to be noted that the induction of an LEM under MetR at the metabolic level is not significantly affected by proliferation or contact inhibition and that the footprint we defined reflects the energetic state under all conditions in L929.

Finally, the results demonstrate that by means of MetR, a low energy metabolism is induced independent of the status of proliferation, which differs substantially from the active and proliferation-oriented metabolism of a (tumour) cell. Our results are of additional importance within tumour therapy, as they show the possibility to further differentiate the metabolism of tumour cells from healthy cells by means of MetR and thus significantly expand the therapy options.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/ 10.3390/cells11030551/s1, Table S1: LCMS results L929 proliferative; Table S2: LCMS results non-proliferative.

Author Contributions: Conceptualization, A.S. and W.S.; methodology, A.S., W.S., J.B., A.C.W. and J.M.V.; software, W.S.; validation, M.E.-M., J.B., C.K. and A.C.W.; formal analysis, A.S. and W.S.; statistical analysis, M.E.-M. and S.H.; investigation, C.K., J.B., A.C.W., J.M.V., A.S. and W.S.; data curation, A.S. and W.S.; writing—original draft preparation, A.S. and M.E.-M.; writing—review and editing, W.S., S.H., C.L. and A.C.K.; visualization, A.S. and W.S.; supervision, A.S. and W.S.; project administration, A.S. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: An overview of the complete LC/MS results has been added to the Supplementary Material. The Raw data and results for the two profiles are added as excel files as S1 (proliferative profile) and S2 (non-proliferative profile).

Acknowledgments: This publication was supported by the Open Access Publication Fund of the University of Wuerzburg.

Conflicts of Interest: The authors declare no conflict of interest.

References

- 1. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [CrossRef]
- Hoffman, R.M.; Yano, S. Tumor-Specific S/G2-Phase Cell Cycle Arrest of Cancer Cells by Methionine Restriction. *Methods Mol. Biol.* 2019, 1866, 49–60. [CrossRef]
- Pennycook, B.R.; Barr, A.R. Restriction point regulation at the crossroads between quiescence and cell proliferation. *FEBS Lett.* 2020, 594, 2046–2060. [CrossRef] [PubMed]
- Vander Heiden, M.G.; Cantley, L.C.; Thompson, C.B. Understanding the Warburg effect: The metabolic requirements of cell proliferation. *Science* 2009, 324, 1029–1033. [CrossRef] [PubMed]
- Hosios, A.M.; Hecht, V.C.; Danai, L.V.; Johnson, M.O.; Rathmell, J.C.; Steinhauser, M.L.; Manalis, S.R.; Vander Heiden, M.G. Amino Acids Rather than Glucose Account for the Majority of Cell Mass in Proliferating Mammalian Cells. *Dev. Cell* 2016, 36, 540–549. [CrossRef] [PubMed]

- 6. Ball, Z.B.; Barnes, R.H.; Visscher, M.B. The effects of dietary caloric restriction on maturity and senescence, with particular reference to fertility and longevity. *Am. J. Physiol.* **1947**, *150*, 511–519. [CrossRef] [PubMed]
- Escobar, K.A.; Cole, N.H.; Mermier, C.M.; VanDusseldorp, T.A. Autophagy and aging: Maintaining the proteome through exercise and caloric restriction. *Aging Cell* 2019, 18, e12876. [CrossRef]
- Mirzaei, H.; Suarez, J.A.; Longo, V.D. Protein and amino acid restriction, aging and disease: From yeast to humans. *Trends Endocrinol. Metab.* 2014, 25, 558–566. [CrossRef] [PubMed]
- Madeo, F.; Zimmermann, A.; Maiuri, M.C.; Kroemer, G. Essential role for autophagy in life span extension. J. Clin. Investig. 2015, 125, 85–93. [CrossRef]
- Gongol, B.; Sari, I.; Bryant, T.; Rosete, G.; Marin, T. AMPK: An Epigenetic Landscape Modulator. *Int. J. Mol. Sci.* 2018, 19, 3238. [CrossRef]
- 11. Longo, V.D.; Kennedy, B.K. Sirtuins in aging and age-related disease. Cell 2006, 126, 257–268. [CrossRef] [PubMed]
- 12. Lauinger, L.; Kaiser, P. Sensing and Signaling of Methionine Metabolism. *Metabolites* 2021, 11, 83. [CrossRef]
- Goberdhan, D.C.; Wilson, C.; Harris, A.L. Amino Acid Sensing by mTORC1: Intracellular Transporters Mark the Spot. *Cell Metab.* 2016, 23, 580–589. [CrossRef] [PubMed]
- 14. Kim, J.; Guan, K.L. mTOR as a central hub of nutrient signalling and cell growth. *Nat. Cell Biol.* **2019**, *21*, 63–71. [CrossRef] [PubMed]
- 15. Gu, X.; Orozco, J.M.; Saxton, R.A.; Condon, K.J.; Liu, G.Y.; Krawczyk, P.A.; Scaria, S.M.; Harper, J.W.; Gygi, S.P.; Sabatini, D.M. SAMTOR is an S-adenosylmethionine sensor for the mTORC1 pathway. *Science* **2017**, *358*, 813–818. [CrossRef]
- 16. Neill, C.O. PI3-kinase/Akt/mTOR signaling: Impaired on/off switches in aging, cognitive decline and Alzheimer's disease. *Exp. Gerontol.* **2013**, *48*, 647–653. [CrossRef] [PubMed]
- 17. Ables, G.P.; Hens, J.R.; Nichenametla, S.N. Methionine restriction beyond life-span extension. *Ann. N. Y. Acad. Sci.* **2016**, 1363, 68–79. [CrossRef] [PubMed]
- Cavuoto, P.; Fenech, M.F. A review of methionine dependency and the role of methionine restriction in cancer growth control and life-span extension. *Cancer Treat. Rev.* 2012, *38*, 726–736. [CrossRef]
- 19. Wanders, D.; Hobson, K.; Ji, X. Methionine Restriction and Cancer Biology. Nutrients 2020, 12, 684. [CrossRef] [PubMed]
- Schmitz, W.; Koderer, C.; El-Mesery, M.; Gubik, S.; Sampers, R.; Straub, A.; Kübler, A.C.; Seher, A. Metabolic Fingerprinting of Murine L929 Fibroblasts as a Cell-Based Tumour Suppressor Model System for Methionine Restriction. *Int. J. Mol. Sci.* 2021, 22, 3039. [CrossRef]
- 21. McClatchey, A.I.; Yap, A.S. Contact inhibition (of proliferation) redux. Curr. Opin Cell. Biol. 2012, 24, 685–694. [CrossRef]
- 22. Mendonsa, A.M.; Na, T.Y.; Gumbiner, B.M. E-cadherin in contact inhibition and cancer. *Oncogene* **2018**, *37*, 4769–4780. [CrossRef]
- Ribatti, D. A revisited concept: Contact inhibition of growth. From cell biology to malignancy. *Exp. Cell Res.* 2017, 359, 17–19.
 [CrossRef]
- 24. Azzu, V.; Valencak, T.G. Energy Metabolism and Ageing in the Mouse: A Mini-Review. Gerontology 2017, 63, 327–336. [CrossRef]
- 25. National Research Council Subcommittee on Laboratory Animal Nutrition. *Nutrient Requirements of Laboratory Animals: Fourth Revised Edition;* National Academies Press: Washington, DC, USA, 1995.
- Melzer, K.; Heydenreich, J.; Schutz, Y.; Renaud, A.; Kayser, B.; M\u00e4der, U. Metabolic Equivalent in Adolescents, Active Adults and Pregnant Women. Nutrients 2016, 8, 438. [CrossRef] [PubMed]
- 27. Speakman, J.R. Body size, energy metabolism and lifespan. J. Exp. Biol. 2005, 208, 1717–1730. [CrossRef]
- Chen, Y.; Zhuang, H.; Chen, X.; Shi, Z.; Wang, X. Spermidine-induced growth inhibition and apoptosis via autophagic activation in cervical cancer. Oncol. Rep. 2018, 39, 2845–2854. [CrossRef]
- Mandal, S.; Mandal, A.; Johansson, H.E.; Orjalo, A.V.; Park, M.H. Depletion of cellular polyamines, spermidine and spermine, causes a total arrest in translation and growth in mammalian cells. *Proc. Natl. Acad. Sci. USA* 2013, *110*, 2169–2174. [CrossRef] [PubMed]
- Gillespie, Z.E.; Pickering, J.; Eskiw, C.H. Better Living through Chemistry: Caloric Restriction (CR) and CR Mimetics Alter Genome Function to Promote Increased Health and Lifespan. *Front. Genet.* 2016, 7, 142. [CrossRef] [PubMed]
- Madeo, F.; Carmona-Gutierrez, D.; Hofer, S.J.; Kroemer, G. Caloric Restriction Mimetics against Age-Associated Disease: Targets, Mechanisms, and Therapeutic Potential. *Cell Metab.* 2019, 29, 592–610. [CrossRef]
- 32. Masiello, M.G.; Verna, R.; Cucina, A.; Bizzarri, M. Physical constraints in cell fate specification. A case in point: Microgravity and phenotypes differentiation. *Prog. Biophys. Mol. Biol.* **2018**, *134*, 55–67. [CrossRef]
- 33. Nencioni, A.; Caffa, I.; Cortellino, S.; Longo, V.D. Fasting and cancer: Molecular mechanisms and clinical application. *Nat. Rev. Cancer* **2018**, *18*, 707–719. [CrossRef]
- Doyle, C.; Kushi, L.H.; Byers, T.; Courneya, K.S.; Demark-Wahnefried, W.; Grant, B.; McTiernan, A.; Rock, C.L.; Thompson, C.; Gansler, T.; et al. Nutrition and physical activity during and after cancer treatment: An American Cancer Society guide for informed choices. *CA Cancer J. Clin.* 2006, *56*, 323–353. [CrossRef] [PubMed]
- 35. Lee, C.; Longo, V.D. Fasting vs dietary restriction in cellular protection and cancer treatment: From model organisms to patients. *Oncogene* **2011**, *30*, 3305–3316. [CrossRef] [PubMed]
- 36. Brandhorst, S.; Wei, M.; Hwang, S.; Morgan, T.E.; Longo, V.D. Short-term calorie and protein restriction provide partial protection from chemotoxicity but do not delay glioma progression. *Exp. Gerontol.* **2013**, *48*, 1120–1128. [CrossRef] [PubMed]

- 37. Obrist, F.; Michels, J.; Durand, S.; Chery, A.; Pol, J.; Levesque, S.; Joseph, A.; Astesana, V.; Pietrocola, F.; Wu, G.S.; et al. Metabolic vulnerability of cisplatin-resistant cancers. *Embo J.* **2018**, *37*, e98597. [CrossRef]
- Bastings, J.; van Eijk, H.M.; Olde Damink, S.W.; Rensen, S.S. d-amino Acids in Health and Disease: A Focus on Cancer. *Nutrients* 2019, 11, 2205. [CrossRef]
- Tabe, Y.; Lorenzi, P.L.; Konopleva, M. Amino acid metabolism in hematologic malignancies and the era of targeted therapy. *Blood* 2019, 134, 1014–1023. [CrossRef]
- 40. Hensley, C.T.; Wasti, A.T.; DeBerardinis, R.J. Glutamine and cancer: Cell biology, physiology, and clinical opportunities. *J. Clin. Investig.* **2013**, *123*, 3678–3684. [CrossRef]
- Schulte, M.L.; Fu, A.; Zhao, P.; Li, J.; Geng, L.; Smith, S.T.; Kondo, J.; Coffey, R.J.; Johnson, M.O.; Rathmell, J.C.; et al. Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models. *Nat. Med.* 2018, 24, 194–202. [CrossRef]
- 42. Matés, J.M.; Di Paola, F.J.; Campos-Sandoval, J.A.; Mazurek, S.; Márquez, J. Therapeutic targeting of glutaminolysis as an essential strategy to combat cancer. *Semin. Cell Dev. Biol.* **2020**, *98*, 34–43. [CrossRef] [PubMed]
- 43. Levine, M.E.; Suarez, J.A.; Brandhorst, S.; Balasubramanian, P.; Cheng, C.W.; Madia, F.; Fontana, L.; Mirisola, M.G.; Guevara-Aguirre, J.; Wan, J.; et al. Low protein intake is associated with a major reduction in IGF-1, cancer, and overall mortality in the 65 and younger but not older population. *Cell Metab.* **2014**, *19*, 407–417. [CrossRef] [PubMed]